Bank of America
SABSW icon

Bank of America’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Bank of America’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$3 – 6687
2025
Q4 		$3 Sell
100
-100
-50% -$3 ﹤0.01% 7252
2025
Q3 		$5 Buy
+200
New +$7 ﹤0.01% 8244
2024
Q3 		– Sell
-200
Closed -$9 – 8376
2024
Q2 		$9 Buy
200
+100
+100% +$4 ﹤0.01% 8095
2024
Q1 		$3 Buy
+100
New +$3 ﹤0.01% 7619

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Bank of America's SABSW Position: Q1 2026 in Review

Bank of America sold out of SAB Biotherapeutics Warrant (SABSW) in Q1 2026, closing a stake of 100 shares — an estimated $3 sold.

Bank of America first reported a position in SABSW in Q1 2024 and held it in 4 quarters. The position peaked at $9 in Q2 2024. 6 funds tracked by Wall St. Rank hold SABSW as of Q1 2026.

  • Bank of America reported no remaining SAB Biotherapeutics Warrant position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 100 SAB Biotherapeutics Warrant shares in Q1 2026, an estimated $3.
  • Bank of America first reported a position in SAB Biotherapeutics Warrant in Q1 2024 and held it in 4 quarters.
  • Bank of America's SAB Biotherapeutics Warrant position peaked at $9 in Q2 2024.
  • 6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.